WallStSmart

Neogen Corporation (NEOG)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 6313% more annual revenue ($56.69B vs $884.00M). NVS leads profitability with a 22.5% profit margin vs -6.3%. NEOG appears more attractively valued with a PEG of 0.66. NVS earns a higher WallStSmart Score of 51/100 (C-).

NEOG

Hold

44

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.24

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NEOGUndervalued (+80.7%)

Margin of Safety

+80.7%

Fair Value

$55.64

Current Price

$12.26

$43.38 discount

UndervaluedFair: $55.64Overvalued
NVSSignificantly Overvalued (-67.2%)

Margin of Safety

-67.2%

Fair Value

$93.84

Current Price

$156.08

$62.24 premium

UndervaluedFair: $93.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NEOG2 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$286.29B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

NEOG4 concerns · Avg: 1.8/10
Return on EquityProfitability
-29.0%2/10

ROE of -29.0% — below average capital efficiency

EPS GrowthGrowth
-85.6%2/10

Earnings declined 85.6%

Altman Z-ScoreHealth
1.242/10

Distress zone — elevated risk

Profit MarginProfitability
-6.3%1/10

Currently unprofitable

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.342/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NEOG

The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : NEOG

The primary concerns for NEOG are Return on Equity, EPS Growth, Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

NEOG profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.

NEOG carries more volatility with a beta of 1.79 — expect wider price swings.

NEOG is growing revenue faster at 6.5% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 44/100), backed by strong 22.5% margins. NEOG offers better value entry with a 80.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Neogen Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?